{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-23-000115","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2023-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.216806+00:00","generated_at":"2026-06-07T21:31:34.559113+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Autolus submits BLA to FDA for cell therapy obe-cel in r/r adult B-ALL","bullets":["BLA for obecabtagene autoleucel (obe-cel) submitted to FDA for relapsed/refractory adult B-cell ALL.","Submission based on Phase 2 FELIX study data presented at ASCO 2023; updated data at ASH December 2023.","Autolus on track to submit Marketing Authorization Application to EMA in H1 2024.","Obe-cel has FDA Orphan Drug, RMAT, and EMA PRIME designations."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-23-000115","json":"https://secwatch.observer/filing/0001730463-23-000115.json","markdown":"https://secwatch.observer/filing/0001730463-23-000115.md","text":"https://secwatch.observer/filing/0001730463-23-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046323000115/0001730463-23-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046323000115/autl-20231127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:31:34.559113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}